Wegovy, used for weight loss and to reduce the risks of cardiovascular disease; Ozempic, used for Type 2 diabetes; and Rybelsus, used for Type 2 diabetes. The drugs are as costly as they are popular.

The CMS listed Ozempic, Rybelsus and Wegovy — all forms of semaglutide — at the top of the list of drugs for which Medicare will the negotiate the price of in 2025. The list price for a one ...

Close to 2.3 million seniors in Medicare are using the semaglutide medications, branded as Ozempic, Rybelsus and Wegovy by Novo Nordisk. Medicare says that the drug added up to more than $14 ...

Besides semaglutide, which Novo Nordisk sells as Ozempic, Rybelsus and Wegovy, the agency also chose other diabetes drugs, respiratory therapies and several cancer treatments. CMS’ treatment of ...

In addition to Wegovy, its sister drug Ozempic, indicated for diabetes, and NVO’s oral GLP-1 agonist Rybelsus have also been selected for the negotiation round. Other drugs included in the list ...